Gennex Laboratories (GENNEX) | Financial Analysis & Statements
Gennex Laboratories Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
341.8M
Gross Profit
119.8M
35.05%
Operating Income
45.7M
13.37%
Net Income
50.2M
14.68%
EPS (Diluted)
₹0.21
Balance Sheet Metrics
Total Assets
2.6B
Total Liabilities
614.5M
Shareholders Equity
1.9B
Debt to Equity
0.32
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Gennex Laboratories Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.4B | 791.0M | 649.6M | 611.8M | 596.3M |
| Cost of Goods Sold | 982.2M | 500.5M | 408.6M | 386.7M | 367.0M |
| Gross Profit | 393.3M | 290.5M | 241.0M | 225.0M | 229.3M |
| Gross Margin % | 28.6% | 36.7% | 37.1% | 36.8% | 38.5% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 33.5M | 21.5M | 30.4M | 25.2M | 27.3M |
| Other Operating Expenses | 109.7M | 95.9M | 89.5M | 68.0M | 62.0M |
| Total Operating Expenses | 143.1M | 117.4M | 119.9M | 93.2M | 89.4M |
| Operating Income | 147.2M | 146.6M | 37.7M | 50.8M | 57.0M |
| Operating Margin % | 10.7% | 18.5% | 5.8% | 8.3% | 9.6% |
| Non-Operating Items | |||||
| Interest Income | 95.7M | 37.9M | 26.6M | 9.0M | 538.2K |
| Interest Expense | 36.1M | 30.8M | 13.5M | 8.8M | 7.4M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 215.5M | 164.9M | 63.7M | 50.9M | 50.6M |
| Income Tax | 32.7M | 33.2M | 14.5M | 11.7M | 10.2M |
| Effective Tax Rate % | 15.2% | 20.1% | 22.8% | 23.0% | 20.2% |
| Net Income | 181.2M | 131.8M | 49.2M | 39.2M | 40.4M |
| Net Margin % | 13.2% | 16.7% | 7.6% | 6.4% | 6.8% |
| Key Metrics | |||||
| EBITDA | 271.7M | 213.6M | 83.6M | 72.5M | 70.6M |
| EPS (Basic) | ₹0.80 | ₹0.67 | ₹0.32 | ₹0.31 | ₹0.30 |
| EPS (Diluted) | ₹0.78 | ₹0.61 | ₹0.32 | ₹0.31 | ₹0.30 |
| Basic Shares Outstanding | 227447674 | 186817062 | 146070205 | 126503000 | 132599530 |
| Diluted Shares Outstanding | 227447674 | 186817062 | 146070205 | 126503000 | 132599530 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Gennex Laboratories Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 545.9M | 602.3M | 142.1M | 74.9M | 1.9M |
| Short-term Investments | 550.2M | 1.2B | 145.0M | 269.0M | 223.5M |
| Accounts Receivable | 141.6M | 178.1M | 94.2M | 113.1M | 89.5M |
| Inventory | 359.4M | 251.7M | 156.9M | 77.4M | 50.2M |
| Other Current Assets | 8.4M | 8.4M | 6.7M | -1 | 11.7M |
| Total Current Assets | 1.8B | 1.6B | 486.8M | 471.8M | 376.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 88.7M | 88.7M | 88.7M | 0 | 0 |
| Goodwill | 29.4M | 29.4M | 61.1M | 0 | - |
| Intangible Assets | 29.4M | 29.4M | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 88.0M | 88.7M | 88.7M | 1 | 2.8M |
| Total Non-Current Assets | 749.1M | 681.7M | 836.3M | 208.4M | 212.3M |
| Total Assets | 2.6B | 2.3B | 1.3B | 680.3M | 589.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 131.6M | 151.8M | 70.8M | 77.4M | 59.4M |
| Short-term Debt | 102.2M | 57.2M | 10.5M | 101.2M | 73.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | 29.2M |
| Total Current Liabilities | 445.6M | 403.0M | 295.1M | 242.1M | 190.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 168.9M | 132.2M | 162.9M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 32.4K | 1.7M |
| Other Non-Current Liabilities | 1 | - | - | -1.0K | 1.0K |
| Total Non-Current Liabilities | 168.9M | 132.2M | 162.9M | 32.4K | 1.7M |
| Total Liabilities | 614.5M | 535.2M | 458.0M | 242.1M | 191.9M |
| Equity | |||||
| Common Stock | 227.4M | 227.4M | 180.2M | 126.5M | 126.5M |
| Retained Earnings | 562.6M | 399.5M | 297.5M | 236.6M | 195.5M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.9B | 1.8B | 865.2M | 438.2M | 397.1M |
| Key Metrics | |||||
| Total Debt | 271.1M | 189.4M | 173.4M | 101.2M | 73.6M |
| Working Capital | 1.4B | 1.2B | 191.7M | 229.7M | 186.5M |
Balance Sheet Composition
Gennex Laboratories Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 214.0M | 164.9M | 63.7M | 52.8M | 50.6M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -229.8M | -668.8M | 57.7M | -3.0M | -26.0M |
| Operating Cash Flow | -75.5M | -511.0M | 108.4M | 67.6M | 31.5M |
| Investing Activities | |||||
| Capital Expenditures | -87.5M | 153.5M | -397.4M | -15.7M | -787.8K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | 0 | -12.5M | 0 | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | 8.2M | 151.2M | -409.9M | -15.7M | -787.8K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 0 | 10.2M | 0 | 0 |
| Debt Repayment | - | -30.7M | -90.7M | -37.0M | -154.9K |
| Financing Cash Flow | 45.0M | 767.6M | 133.2M | -46.4M | 23.6M |
| Free Cash Flow | -197.4M | -466.9M | -161.1M | 103.1M | -15.2M |
| Net Change in Cash | -22.2M | 407.7M | -168.4M | 5.5M | 54.3M |
Cash Flow Trend
Gennex Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
14.37
Price to Book
1.19
Price to Sales
1.68
PEG Ratio
-7.90
Profitability Ratios
Profit Margin
12.59%
Operating Margin
13.54%
Return on Equity
9.31%
Return on Assets
7.08%
Financial Health
Current Ratio
3.67
Debt to Equity
39.79
Beta
0.60
Per Share Data
EPS (TTM)
₹0.73
Book Value per Share
₹8.78
Revenue per Share
₹6.03
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| GENNEX | 2.5B | 14.37 | 1.19 | 9.31% | 12.59% | 39.79 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





